Infertility affects millions globally, with significant prevalence in India due to conditions like endometriosis and polycystic ovarian syndrome (PCOS). Dydrogesterone, a synthetic progesterone, has demonstrated efficacy in managing endometriosis, recurrent pregnancy loss (RPL), and infertility. Endometriosis, affecting 10% of reproductive-aged women, often leads to infertility and recurrent pain despite surgical interventions. Dydrogesterone 20 mg effectively reduces chronic pelvic pain and improves quality of life in these patients. In infertility management, dydrogesterone enhances luteal phase support (LPS), leading to higher pregnancy rates and better reproductive outcomes compared to other progesterone forms. It is particularly beneficial in in vitro fertilization (IVF) and intrauterine insemination (IUI) cycles, showing improved patient compliance and reduced side effects. For RPL, dydrogesterone stabilizes the endometrial environment, supporting implantation and early embryonic development. Its use in PCOS aids in menstrual regulation and pregnancy preparation without inhibiting ovulation. Expert opinions from Indian gynaecologists highlight the need for tailored dydrogesterone protocols to address the unique challenges in Indian healthcare. This document gathers insights from these experts, emphasizing the therapeutic potential of dydrogesterone in gynaecology, obstetrics, and infertility management
